Evidence review
Saw palmetto for BPH and urinary symptoms: evidence reviewed
The strongest evidence indicates that saw palmetto alone produces little to no improvement in urinary symptoms from benign prostatic hyperplasia compared with placebo. That conclusion rests on a 2023 Cochrane review and large independent US trials, including one that increased the dose without benefit. Industry-linked analyses of a specific hexanic extract are more positive, and guidelines disagree about whether it has any role.
Ingredient evidence ≠ product proof
This page reviews research on an ingredient. It does not show that any branded supplement containing that ingredient works, because commercial products may use a different form, dose or combination, and are rarely tested themselves. This is an evidence page: it contains no affiliate links.
The research question
Does saw palmetto improve lower urinary tract symptoms caused by benign prostatic hyperplasia compared with placebo?
Evidence table: population → dose → duration → result → limitations
| Study | Population | Dose / intervention | Duration | Result | Limitations |
|---|---|---|---|---|---|
| Cochrane, 2023 | Men with BPH-related urinary symptoms | Saw palmetto alone or combined, vs placebo | Varied | Little to no symptom improvement (mainly high/moderate certainty) | Combination evidence low certainty |
| STEP trial (Bent et al., NEJM 2006) | Men with moderate-to-severe BPH symptoms | Saw palmetto extract vs placebo | 1 year | No significant benefit over placebo | Single extract |
| CAMUS trial (Barry et al., JAMA 2011) | Men with BPH symptoms | Increasing doses of saw palmetto extract vs placebo | 72 weeks | No benefit over placebo, including at higher doses | Single extract |
| Permixon meta-analysis (BJU Int 2018) | RCTs and observational studies of one hexanic extract | Hexanic extract (Permixon) | Varied | More favourable effects reported for this extract | Includes observational data; industry-linked |
| Drugs in Context review, 2026 | Studies published 2020–2025 | Various extracts including hexanic and combinations | Varied | Reported more consistent signals with hexanic and beta-sitosterol-enriched preparations | Mixed designs including open-label and observational |
What the results show
Placebo-controlled evidence is the most relevant for deciding whether an ingredient itself works, because urinary symptoms fluctuate and placebo responses are substantial. On that evidence, saw palmetto performs no better than placebo. Supporters argue that extracts differ and that a specific hexanic extract performs better; the analyses supporting that view include observational studies and are linked to the manufacturer. According to an American Family Physician Cochrane summary, NICE recommends not offering phytotherapy, the 2021 AUA guideline does not include it, and the 2023 EAU guideline gives a weak recommendation with a warning that benefit may be modest.
What the research does not prove
- That saw palmetto shrinks the prostate.
- That it prevents prostate cancer or affects its course.
- That combination prostate supplements work because they contain saw palmetto.
- That it is equivalent to prescription BPH treatment.
Safety
- Generally well tolerated; mild digestive upset and headache are reported (NCCIH).
- The main practical risk is delayed assessment of urinary symptoms that may have other causes.
- Tell your prescriber if you take BPH or hormonal medicines, or before surgery.
Limitations of the evidence base
- Different extracts across trials make “saw palmetto” a non-uniform intervention.
- Industry involvement in positive analyses of branded extracts.
- Symptom-score outcomes are subjective and placebo-sensitive.
Frequently asked questions
Does saw palmetto work for BPH?
Placebo-controlled evidence, including the 2023 Cochrane review, indicates little to no symptom improvement from saw palmetto alone.
Does a higher dose help?
The CAMUS trial increased the dose and still found no benefit over placebo.
Why do some sources still recommend it?
Some analyses of a specific hexanic extract are more positive, and the European guideline gives a weak recommendation; independent placebo-controlled trials are negative.
Related on FactoWiki
Saw palmetto ingredient guide · Saw palmetto vs beta-sitosterol · Beta-sitosterol evidence review · Prostate category
References
- Franco JVA, et al. Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement. Cochrane Database Syst Rev. 2023. PMID 37345871
- Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med. 2006;354(6):557–566.
- Barry MJ, Meleth S, Lee JY, et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA. 2011;306:1344–1351.
- Efficacy and safety of a hexanic extract of Serenoa repens (Permixon®) for LUTS/BPH: systematic review and meta-analysis. BJU Int. 2018;122:1049–1065.
- Drugs in Context systematic review of recent Serenoa repens evidence, 2026. Link
- American Family Physician: Cochrane summary on saw palmetto, 2024. Link
- NCCIH: Saw palmetto. Link